Navigation Links
The benefits of reperfusion therapy
Date:9/1/2009

Barcelona, Spain, 1 September: The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half. AMI is caused by a sudden blockage of a coronary artery, one of the vessels supplying the heart muscle with oxygen and nutrients. Effective reperfusion therapy provides a timely and sustainable reopening of the blockage.

The WHO MONICA* project showed that in European centres in the mid-1990s, in-hospital mortality of AMI patients was 13%; this was a time when only about 40% of the patients had reperfusion therapy. Today, specialist centres can provide effective reperfusion therapy to more than 90% of their AMI patients. In such centres, in-hospital mortality rate is now as low as around 5%.

The first development in reperfusion therapy was the application of fibrinolytic agents to dissolve the blood clots causing the vessel blockage. Analysis of data from earlier studies reveals that, on average, fibrinolytic agents can reduce infarct-related mortality rate by 18% compared with no reperfusion therapy. Fibrinolytic therapy is universally available and is still the mainstay of reperfusion therapy where healthcare resources are limited.

More modern catheter-based reperfusion strategies, however, are more effective. Compared with what can be achieved by clot-buster drugs, catheter-based therapy reduces infarct-related mortality by a further 37%. Using this approach, the coronary artery is re-opened mechanically with a balloon catheter and vessel patency is usually stabilised by placement of a stent. Potent adjunct antithrombotic drug therapy prevents recurrent clot formation. The larger survival benefit from catheter-based reperfusion therapy as compared with fibrinolytic therapy can be attributed to a higher success rate in reopening blocked vessels (90% versus 40-60%) and to better sustainability.

If no reperfusion therapy is initiated and the infarct-related coronary artery continues to be blocked, the heart muscle supplied by this vessel is destined to die. Loss of functional heart muscle can cause death by pump failure or break-down of normal heart rhythm. Moreover, it is a major cause of long-term illness due to heart failure. Effective reperfusion therapy can prevent the death of heart muscle cells and salvages a large proportion of the heart muscle at risk. In this way, reperfusion therapy effectively prevents chronic illness. The percentage of heart-muscle salvage varies to a large extent on reperfusion modality, timing of reperfusion and patient characteristics.

Catheter-based reperfusion usually salvages around 60% of the heart muscle at risk. For the individual patient this often means a normal life, despite having suffered a heart attack.


'/>"/>

Contact: Jacquelline Partarrieu
jpartarrieu@escardio.org
0034-600-919-617
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Practice-based intervention has sustained benefits for children and families
2. Manic phase of bipolar disorder benefits from breast cancer medication
3. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
4. Smaller breast reduction surgeries provide health benefits and should be reimbursed
5. Cholesterol byproduct blocks heart health benefits of estrogen
6. A Place for Mom, Nations Largest Senior Care Referral Service, Fills a Gap in Employee Benefits
7. New Herbal Water Creating Taste Sensation: Ayalas Herbal Water Has No Calories, No Preservatives and No Artificial Additives. Just All the Natural Benefits of Herbs!
8. Hazards of using crib bumper pads outweigh their benefits
9. Dominium Benefits Experiencing Dynamic Growth
10. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
11. Physiotherapy has short-term benefits for patients after knee surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... Illustrate, Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time ... Rights (OCR) HIPAA audit and properly satisfy the law. , Thanks to the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and social campaign, “Humans With Vaginas.” The goal is to ignite conversation via ... non-toxic personal care products. The brand has declared September “Humans with Vaginas” month, ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment ... 8, and Monday, September 11, off work and rolled up their sleeves to help ... to local homes to start the process of rebuilding. , CORDA founder Bonner C. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology: